Peter Lundberg Joins Solexa as VP And Chief Technical Officer; Company Builds Management Team to Be a Future Genomics Platform Leader

Mr. Tony Smith, who had served as the chief technology officer
of Solexa, Ltd until its recent business combination with Lynx
Therapeutics, has been promoted to the role of vice president
and chief scientific officer. Smith will continue to be
responsible for all research and development activities in the
UK and will now be the senior manager in the UK. Solexa will continue to provide high volume,
short read DNA sequencing services from its Hayward production
facility via the Lynx bead-based technology platform until the new
fully automated Cluster-SBS instruments begin replacing the older
systems later this year and into early 2006. The SynX subsidiary offers a line of
point-of-care diagnostic tests and is building expertise in cardiac related
health conditions.nanogen.

Lynx Stockholders Overwhelmingly Approve Solexa-Lynx Business Combination

"We would like to thank our stockholders for demonstrating
overwhelming support for this business combination, which we believe
will result in significant strategic and financial benefits for our
company," said Mary L., Lynx's acting chief executive
officer . "We have been working closely with Solexa since we announced
the definitive agreement to combine our companies last September in an
effort to accelerate the development and commercialization of DNA
technology we jointly acquired approximately one year ago." For more information, visit Solexa 's Web site at
www.

homozygous splice

"I am delighted we are able to attract an executive of Peter's
caliber as he brings both great technical depth in our field and
extensive experience as a manager," said John West, Solexa's chief
executive officer.
"Tony provides exceptional leadership, which is evident in his team's
ability to complete our first full-genome sequence announced earlier
today. In an unrelated transaction recently, Solexa received
an additional $14 million in venture capital financing , bringing its
total to date to over $40 million.

tagsorter ests

Lundberg brings almost 20 years of industry experience , most
recently as vice president, DNA platforms R+D at the Applied
Biosystems unit of Applera Corporation. This role underscores
the company's ongoing commitment to its service business and
to its current customers. The SBU can act similarly to the commonly-used
biotin/strepavidin binding pair but many different SBU pairs can be
synthesized. There are a number of important factors that could cause
the results of Lynx to differ materially from those indicated by these
forward -looking statements, including, among others, risks detailed
from time to time in Lynx's SEC reports , including its Annual Report
on Form 10-K for the year ended December 31, 2003, as amended, its
Quarterly Report on Form 10-Q for the period ended September 30, 2004
and its Proxy Statement/Prospectus filed pursuant to Rule 424(b)(3) on
January 24, 2005.

putative phylogeny

S. Patent
No.S. This sequence pattern
matching software is designed to provide a superior method for analyzing a
large amount of data to identify unique amino acid sequences quickly, which is
key to proteomic biomarker discovery. In a multiplex amplification, unique primers can be paired with
unique SBUs so that upon detection on a microarray , the amplified products
array themselves automatically to bind with a complementary SBU attached to
the array.
Lynx expects the closing of the business combination to occur later
this month .

genex reagent

+ CAMBRIDGE, U. In this position, he was
responsible for the development of instrument systems spanning DNA
sequencing, gene expression and genotyping.
Research and clinical reference labs use the highly accurate and reliable
NanoChip(R) Molecular Biology Workstation, NanoChip(R) Electronic Microarray
and broad suite of analyte specific reagents to develop diagnostic tests for
variety of diseases .----Lynx
Therapeutics, Inc.

predictor phylogeny

S. 6,893,822,
"Enzymatic modification of a nucleic acid-synthetic binding unit conjugate. Birndorf, Nanogen's chairman of the board and chief executive officer.

Nanogen Forward-Looking Statement
This press release contains forward-looking statements that are subject to
risks and uncertainties that could cause actual results to differ materially
from those set forth in the forward-looking statements, including whether
patents owned or licensed by Nanogen will be developed into products, whether
the patents owned by Nanogen offer any protection against competitors with
competing technologies, whether products under development can be successfully
developed and commercialized, whether results reported by our customers or
partners can be identically replicated , and other risks and uncertainties
discussed under the caption "Factors That May Affect Results" and elsewhere in
Nanogen's Form 10-K or Form 10-Q most recently filed with the Securities and
Exchange Commission.solexa.

Genetics:Software provides links to software for genetic research and teaching from the cellular level up to genetics of populations.

ests genomes

Lundberg assumed responsibility for development of that company's
array platforms. West.
"The amino acid matching technology has been used internally to expedite
protein biomarker discovery, providing Nanogen the potential to identify novel
biomarkers of disease for future diagnostic product development.

collation tagsorter

Lundberg
received his BS and MS degrees in Engineering Physics at Chalmers
Technical University in Sweden. Lundberg's appointment, Solexa announced the
following changes in management responsibility:

Dr."

About Solexa

Solexa is developing DNA sequencing systems for the comprehensive
and economical analysis of whole genomes .

About Solexa

Solexa, Ltd, a private company headquartered outside Cambridge,
U.

genomic linkage

I believe this system's
performance can have considerable impact on the market, both in gene
expression and in DNA sequencing.

Dr.
Solexa was formed by the recent combination of Solexa Limited with
Lynx Therapeutics, Inc. The bead-based systems
are mainly used for genome-wide, comprehensive gene expression and
small RNA analysis, and the Cluster-SBS technology will enable
sequencing services for the broad genome analysis community.

putative ests

Mr. This led to the introduction of its gene expression
array platform and its multiplexed genotyping assay. 6,891,154, "Amino Acid Sequence Pattern Matching " and No. The '822 patent adds to a family of technologies that allows
for novel methods of active construction of arrays of immobilized nucleic
acids utilizing prefabricated arrays of SBUs.

The closing of the Solexa-Lynx business combination is subject
to, among other conditions, the acceptance by Solexa shareholders of
Lynx's offer to acquire the entire issued share capital of Solexa . Any statements contained in this press release that are not
statements of historical fact may be deemed to be forward-looking
statements.

reagent genex

Business Editors/Health/Medical Writers

HAYWARD , Calif. With experience in these applications, Mr. Lundberg said, "I am extremely
optimistic about the potential for the Solexa's technology and I look
forward to launching the company's new system . Mary Schramke, who headed Lynx product development and
served as Lynx's interim chief executive officer prior to the
business combination, has taken the position of vice president
and general manager of genomic services. Mary brings an important combination of scientific and
business ability and has been a very effective partner in bringing the
recently announced combination of Lynx and Solexa to completion. Solexa
expects to begin testing Cluster-SBS instruments in its production
facility by the end of this year and to begin broad commercial sale of
instruments in early 2006.
The SBUs only bind to a very specific complement SBU, which may be on a
microarray chip. (Nasdaq:LYNX) today announced that Lynx
stockholders have approved all six proposed items included in the
Company's Proxy Statement/Prospectus at today's Annual Meeting of
Stockholders, including the proposed business combination with United
Kingdom-based Solexa Limited.D.

About Lynx

Lynx believes that it is a leader in the development and
application of novel genomic analysis solutions.

genomes splice

This is a terrific accomplishment and we complement his entire
team's efforts. These systems are intended
for use by customers in a wide range of applications from basic
research through the development and implementation of personalized
medicine.

Nanogen's advanced diagnostics provide physicians and patients worldwide
with sophisticated information to predict, diagnose and treat disease."
Other proposals in the Proxy Statement/Prospectus approved by
stockholders included (i) the sale and issuance of shares of Lynx
common stock and the change of control in Lynx , which may occur as a
result of such sale or issuance of shares of Lynx common stock; (ii)
an amendment to effect a reverse stock split at a ratio of up to
one-for-four shares, and an amendment to increase the number of shares
of the Company's common stock authorized for issuance by 2 million
shares; (iii) the election of six directors to the board; (iv) an
amendment to Lynx's stock option plan to increase the number of shares
authorized for issuance thereunder by 2 million if the proposed
business combination with Solexa is completed or 300,000 shares if the
transaction is not completed; (v) and the ratification of the
appointment of Ernst + Young LLP as Lynx's independent registered
public accounting firm for the fiscal year ending December 31, 2004.

genesifter genomes

SAN DIEGO, Nanogen, Inc ."
The '154 patent relates to software designed for amino acid sequencing
pattern matching and determining the number of possible sequences consistent
with the molecular weight of the amino acid.

Business Editors/Health/Medical Writers

HAYWARD, Calif.

microarray genomic

Any statements contained
in this press release that are not statements of historical fact may
be deemed to be forward-looking statements. Schramke, Ph.

tagsorter collation

He holds an MBA, with a concentration
in Finance, from the University of Connecticut. The essential task of
determining the amino acid sequence of an unknown protein depends on sorting
through a large amount of data generated by a mass spectrometer, which can be
time consuming and difficult. Nanogen's ten years of pioneering research involving
nanotechnology may also have future applications in medical diagnostics,
biowarfare and other industries. Nanogen disclaims any intent or obligation to update these
forward-looking statements.

mapmaker predictor

(Nasdaq:SLXA) today announced that Peter Lundberg
has joined the company as vice president and chief technical officer. His career association
with Applera began in 1985 when he joined PerkinElmer, where he led
the development of early preparative PCR systems, a role that enabled
his move to Applied Biosystems' PCR group.

"I am committed to building a world-class
management team to drive the growth of Solexa and Peter will be a key
member. Patent and Trademark Office, including U. Nanogen also offers a broad portfolio of patented
nucleic acids chemistries and molecular tools that accelerate genomic analysis
and are compatible with many systems.K.com. As applied
to gene expression analysis, MPSS(TM) provides comprehensive and
quantitative digital information important to modern systems biology
research in the pharmaceutical, biotechnology and agricultural
industries.

splice genomes

K. The systems Solexa is developing are designed to provide very
large amounts of information about individual genomes including the
entire individual human genomic sequence, and to do so economically.com. Of votes cast with respect to this
proposal, over 97% were in favor of the proposed combination with
Solexa. The ability to read individual genomes
quickly and economically will be a fundamental tool in the development
of the biological and medical sciences in the 21st Century.

constitutive splice

"
Nanogen's growing portfolio of 128 U. In addition,
our SBU technology promotes specificity and flexibility in the use of our
microarrays . The software was developed by SynX
Pharma, a Nanogen subsidiary. Solexa's
ultimate goal is to develop systems capable of achieving the so called
"$1,000 genome. For more information, visit Lynx 's Web site at
www.

microarray splice

Mr.

Nanogen Issued Patents for Biomarker Discovery and Nucleic Acid Manipulation Technologies

About Nanogen, Inc., is developing systems for the comprehensive and economical
analysis of individual genomes.

Software covered by other categories, such as evolution, phylogeny and general molecular biology will be specifically excluded.

deletion reagent

"I would also like to take this opportunity to recognize the
accomplishments of Tony Smith and Mary Schramke," added Mr. In addition, variables such as noise
filtration, offsets in samples and multiple sample preparation methods can
result in unacceptable readings from several samples. Lynx's
Massively Parallel Sequencing System (MPSS (TM)) consists of
proprietary instrumentation and software that are used to analyze
millions of DNA molecules in parallel, enabling genome structure
characterization at an unprecedented level of resolution.com
This press release contains "forward-looking" statements,
including statements related to Lynx's continued listing on the Nasdaq
SmallCap Market and the proposed business combination between Lynx and
Solexa.

genesifter reagent

Present methods generally
provide insufficient information and are costly , which has inhibited
progress, for instance in understanding the genetic components of
common human diseases and the variable response of individuals to
drugs. There are a number of important
factors that could cause the results of Solexa to differ materially
from those indicated by these forward-looking statements including,
among others, risks detailed from time to time in the Company 's SEC
reports, including its Annual Report on Form 10-K for the year ended
December 31, 2003, as amended, its Quarterly Report on Form 10-Q for
the period ended September 30, 2004 and its Proxy Statement/Prospectus
filed pursuant to Rule 424(b)(3) on January 24, 2005.

pegasys collation

----March 10,
2005- -Solexa, Inc. At Applied Biosystems, he
served as director of engineering in the company's PCR business unit
responsible for overseeing the technical development that led to the
rapid growth of real -time PCR, including its application to both gene
expression and genotyping. The amount of information required about individual genomes
depends upon the scientific application.. Words such as "believes ," "anticipates," "plans,"
"predicts," "expects," "envisions," "hopes," "estimates," "intends,"
"will," "continue," "may," "potential," "should," "confident," "could"
and similar expressions are intended to identify forward-looking
statements.

linkage genomic

Lundberg will be responsible for all research and development
activities at the company's California location.
Commenting on his appointment, Mr . Words such as "believes,"
"anticipates," "plans," "predicts," "expects," "envisions," "hopes,"
"estimates," "intends," "will," "continue," "may," "potential,"
"should," "confident," "could" and similar expressions are intended to
identify forward-looking statements. Alternatively a SBU can be used as a label to detect a specific
nucleic acid. For additional information please visit
Nanogen 's website at http://www. Lynx does not undertake any obligation to update
forward-looking statements .

collation modelled

"

Other Management Appointments

Concurrent with Mr. patents now includes intellectual
property related to novel biomarker discovery technology and methods of
isolating nucleic acids on a microarray.
"The technology that these patents cover can improve our ability to find
appropriate biomarkers and can improve the use of multiplexing in diagnostics,
helping us to bring valuable diagnostic solutions to the market," said Howard
C.
The '822 patent relates to methods using novel synthetic binding units
(SBUs) with very high specificity and sensitivity, linked to nucleic acids as
primers in a PCR or other nucleic acid amplification and detection reaction. These forward-looking statements speak only as of the
date hereof. Today's
announcement of shareholder approval for the business combination and
the other measures necessary to complete this transaction mark a very
important milestone in our quest to build a leading company delivering
market-transforming DNA sequencing technologies . By "novel," Lynx
means next generation technology that will take the engagement of
thought leaders before broader commercial acceptance can occur.lynxgen.

homozygous genesifter

Dr.
This press release contains "forward -looking" statements,
including statements related to the current views of Solexa management
as to future products, product development, the expansion and success
of Solexa's commercial application of its genomics technologies, and
the future financial performance of Solexa. Solexa does not
undertake any obligation to update forward-looking statements. (Nasdaq: NGEN),
developer of advanced diagnostic products, announced today it was issued two
patents from the U.